* To delay European application until 2012
* Will conduct additional two-year study
TOKYO, - Takeda Pharmaceutical Co (4502.T) said it would not seek European approval for a key drug candidate that it has positioned as a successor to its best-selling diabetes drug until 2012, instead of its original plan to submit an application this year.
Japan's largest drugmaker said it would conduct an additional two-year clinical study for alogliptin, or SYR-322 so that more robust data is available to ensure its approval in Europe.
The delay also affects its application for a combination drug of alogliptin and Actos, its best-selling diabetes drug.
Takeda suffered a major setback this year after U.S. regulators said they wanted more data before reviewing alogliptin -- a development that sent the drugmaker's shares plunging. [ID:nT239013]
Actos accounts for roughly a quarter of Takeda's revenues and will lose U.S. patent protection in 2011.
Takeda edged up 0.3 percent to 3,820 yen, outperforming a 0.6 percent decline in the benchmark Nikkei average .N225.
No comments:
Post a Comment